Belite Bio, Inc (BLTE)

Market Cap	1.99B
Revenue (ttm)	n/a
Net Income (ttm)	-33.03M
Shares Out	30.88M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,778
Open	63.97
Previous Close	64.12
Day's Range	63.10 - 64.52
52-Week Range	31.01 - 86.53
Beta	-1.64
Analysts	Strong Buy
Price Target	89.00 (+37.94%)
Earnings Date	Nov 12, 2024

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy tha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: BLTE
• Website: https://www.belitebio.com

Analyst Forecast

According to 4 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price forecast is $89.0, which is an increase of 37.94% from the latest price.

Price Target

$89.0

(37.94% upside)

Analyst Consensus: Strong Buy